Corcept Therapeutics (CORT) announced the start of BELLA, a Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab evaluating efficacy and safety in patients with platinum-resistant ovarian cancer. “In our pivotal Phase 3 ROSELLA trial, treatment with relacorilant and nab-paclitaxel improved patients’ progression-free and overall survival, without increasing their side effect burden,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer. “BELLA will examine whether combining relacorilant with two medications – nab-paclitaxel and bevacizumab – will offer patients an additional treatment option.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Corcept Therapeutics price target raised to $131 from $128 at Piper Sandler
- Biotech Alert: Searches spiking for these stocks today
- Corcept Therapeutics Stock (CORT) Rockets Up 100% After Groundbreaking Cancer Trial Success
- Corcept Therapeutics price target raised to $142 from $130 at Canaccord
- Buy Recommendation for Corcept Therapeutics Driven by Promising Phase 3 ROSELLA Study Results and Market Expansion Potential